Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 17/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.64 |
| ▸ | RORA | P35398 | 4/20 | 0.64 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.64 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.64 |
| ▸ | RORB | Q92753 | 4/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.64 |
| ▸ | CPT2 | P23786 | 3/20 | 0.56 |
| ▸ | CPT1A | P50416 | 3/20 | 0.56 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021975 | 0.95 | RORC (0.75) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL19648376 | 0.88 | CPT1A (0.71) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL28823982 | 0.86 | RORC (0.66) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5022255 | 0.83 | RORC (0.71) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5021967 | 0.83 | CPT1A (0.60) | RORCNR1H2NR1H3CPT2CPT1A | |
| SCHEMBL5021973 | 0.83 | RORC (0.56) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5023440 | 0.82 | RORC (0.91) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5022493 | 0.82 | RORC (0.71) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5022057 | 0.82 | RORC (0.59) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5022066 | 0.82 | RORC (0.71) | RORCNR1I2RORANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512111-B2 | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512111-B2 | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | RORC 1/4885NR1I2 9/4885RORA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.